Investigational Only. Product candidates are investigational and not approved by the FDA or Health Canada. Content is non-promotional and for informational / investor-relations purposes only.
PantarhinTM is pioneering a new approach to investigating enzyme-based strategies in atherosclerosis biology.
Our innovative DUALASETM, investigating Enzyme-Based Approaches in Cardiovascular Biologytargets the root cause by breaking down plaque and restoring vessel elasticity.
Driven by Innovation, Focused on Patient Well-being – Pantarhin Pharma’s Mission. Developing groundbreaking treatments for atherosclerosis is designed to modulate extracellular-matrix and lipid components associated with atherosclerosis; clinical evaluation pending.
Pantarhin Pharma Inc. is a biopharmaceutical company dedicated to the discovery and development of innovative therapies for the treatment of atherosclerosis. We are focused on addressing the limitations of current treatments by targeting the underlying causes of the disease.
Our lead product, DUALASETM, is a novel, dual-action-like hyaluronidase designed to break down atherosclerotic plaques and restore vascular elasticity. Advancing research programs in cardiovascular biology. We are committed to rigorous scientific research and clinical development to bring transformative treatments to patients in need.
Committed to developing biotechnologically produced therapies that address the root causes of atherosclerosis.
DUALASETM
Research Program in Atherosclerosis
BELACTTM DUALASETM is a biotechnologically produced enzyme that combines the activities of PH20 and HYAL4 in a single substance. It is designed to modulate extracellular-matrix and lipid components associated with atherosclerosis; clinical evaluation pending.
Both hyaluronic acid (HA) and sulfated glycosaminoglycans (GAGs), key components of atherosclerotic plaques, while preserving the structure of blood vessels. This promotes plaque breakdown and restoration of vessel elasticity.